Fig. 2: Clinical and molecular data of non-small cell lung cancer patients (Patients 1–90).

Heatmap representing clinical features (i.e., 1. sex, 2. histology, 3. stage of disease) and molecular analysis (i.e., 4. tumor tissue next-generation sequencing (NGS), 5. tumor tissue fusion and rearrangement analysis, plasma-derived circulating cell-free DNA (ccfDNA) analysis using the UltraSEEK Lung Panel). For variants that can be detected in plasma with UltraSEEK (6. green columns), it was indicated whether this variant was identified in tumor tissue only (orange), plasma only (blue), or in both tumor tissue and in plasma (orange and blue). Variants that were not covered by the UltraSEEK Lung Panel (6. blue columns), as well as fusions and exon skipping (6. orange columns) were displayed separately. For fusions, the fusion partner gene is indicated in the box. If no fusion partner gene was specified, the fusion gene itself was stated in the box. For MET variants, exon 14 indicated that a mutation resulted in skipping of exon 14. Genes that were not analyzed in tumor tissue were highlighted in grey. Based on the molecular profile, eligibility for targeted treatment is indicated (column 7). *G12_G13delinsCA. IHC, immunohistochemistry; FISH, fluorescence in situ hybridization.